BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19380355)

  • 1. Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040.
    Henderson YC; Ahn SH; Clayman GL
    Arch Otolaryngol Head Neck Surg; 2009 Apr; 135(4):347-54. PubMed ID: 19380355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.
    Henderson YC; Chen Y; Frederick MJ; Lai SY; Clayman GL
    Mol Cancer Ther; 2010 Jul; 9(7):1968-76. PubMed ID: 20587665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.
    Henderson YC; Ahn SH; Kang Y; Clayman GL
    Clin Cancer Res; 2008 Aug; 14(15):4908-4914. PubMed ID: 18676765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
    Henderson YC; Fredrick MJ; Clayman GL
    Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.
    Jeong WJ; Mo JH; Park MW; Choi IJ; An SY; Jeon EH; Ahn SH
    Cancer Biol Ther; 2011 Sep; 12(5):458-65. PubMed ID: 21725210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Src inhibitors in suppression of papillary thyroid carcinoma growth.
    Henderson YC; Toro-Serra R; Chen Y; Ryu J; Frederick MJ; Zhou G; Gallick GE; Lai SY; Clayman GL
    Head Neck; 2014 Mar; 36(3):375-84. PubMed ID: 23729178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
    Guerra A; Zeppa P; Bifulco M; Vitale M
    Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma.
    Dinets A; Hulchiy M; Sofiadis A; Ghaderi M; Höög A; Larsson C; Zedenius J
    Eur J Endocrinol; 2012 Jun; 166(6):1049-60. PubMed ID: 22457234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Frequency of RET/PTC rearrangement and somatic BRAF mutation in papillary thyroid cancer].
    Rumiantsev PO; Zaletaev DV; Vasil'ev EV; Saenko VA; Il'in AA; Rumiantseva UV; Abrosimov AIu; Medvedev VS
    Vopr Onkol; 2006; 52(2):145-9. PubMed ID: 17195637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
    Pizzolanti G; Russo L; Richiusa P; Bronte V; Nuara RB; Rodolico V; Amato MC; Smeraldi L; Sisto PS; Nucera M; Bommarito A; Citarrella R; Lo Coco R; Cabibi D; Lo Coco A; Frasca F; Gulotta G; Latteri MA; Modica G; Galluzzo A; Giordano C
    Thyroid; 2007 Nov; 17(11):1109-15. PubMed ID: 17727338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
    Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
    Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
    Liu D; Liu Z; Jiang D; Dackiw AP; Xing M
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4686-95. PubMed ID: 17911174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.
    Schweppe RE; Kerege AA; Sharma V; Poczobutt JM; Gutierrez-Hartmann A; Grzywa RL; Haugen BR
    Thyroid; 2009 Aug; 19(8):825-35. PubMed ID: 19500021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The correlation between BRAF mutations, RET/PTC rearrangements and platelet-derived growth factor B expression in papillary thyroid carcinomas].
    Wang P; Wang YG; Zhao WJ; Fu YD; Wang L; Wang F; Zhao SH
    Zhonghua Nei Ke Za Zhi; 2012 Dec; 51(12):987-91. PubMed ID: 23327964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC.
    Rusciano MR; Salzano M; Monaco S; Sapio MR; Illario M; De Falco V; Santoro M; Campiglia P; Pastore L; Fenzi G; Rossi G; Vitale M
    Endocr Relat Cancer; 2010 Mar; 17(1):113-23. PubMed ID: 19903742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of silencing RET/PTC1 junction oncogene in human papillary thyroid carcinoma cells.
    Gilbert-Sirieix M; Ripoche H; Malvy C; Massaad-Massade L
    Thyroid; 2010 Oct; 20(10):1053-65. PubMed ID: 20615140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.